News | February 11, 2026
Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The company’s EBITDA margin remained resilient above 20%
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
Subscribe To Our Newsletter & Stay Updated
